Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 16:00
12/01/21
12/01
16:00
12/01/21
16:00
JNJ

Johnson & Johnson

$158.65 /

+2.69 (+1.72%)

, PFE

Pfizer

$55.02 /

+1.3 (+2.42%)

, INSM

Insmed

$27.07 /

-0.44 (-1.60%)

, XLRN

Acceleron

$178.79 /

+ (+0.00%)

, GOSS

Gossamer Bio

$10.91 /

+0.07 (+0.65%)

, UTHR

United Therapeutics

$189.57 /

+0.41 (+0.22%)

, PHAS

PhaseBio

$1.92 /

-0.16 (-7.69%)

, TENX

Tenax Therapeutics

$1.23 /

-0.05 (-3.91%)

, AVTE

Aerovate Therapeutics

$13.43 /

-0.3 (-2.18%)

Large Cap and Biopharma…

Large Cap and Biopharma Analysts Chen & Kim and Biotech Analyst Cheng, along with Dr. Ryan, Cardiologist and Dr. Berger, Cardiologist, discuss new and existing treatments for Pulmonary Arterial Hypertension (PAH) on an Analyst/Industry conference call to be held on December 7 at 1 pm.

ShowHide Related Items >><<
XLRN Acceleron
$178.79 /

+ (+0.00%)

UTHR United Therapeutics
$189.57 /

+0.41 (+0.22%)

TENX Tenax Therapeutics
$1.23 /

-0.05 (-3.91%)

PHAS PhaseBio
$1.92 /

-0.16 (-7.69%)

PFE Pfizer
$55.02 /

+1.3 (+2.42%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

GOSS Gossamer Bio
$10.91 /

+0.07 (+0.65%)

AVTE Aerovate Therapeutics
$13.43 /

-0.3 (-2.18%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
PFE Pfizer
$55.02 /

+1.3 (+2.42%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
INSM Insmed
$27.07 /

-0.44 (-1.60%)

11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
10/19/21 Morgan Stanley
Insmed assumed with an Overweight at Morgan Stanley
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
XLRN Acceleron
$178.79 /

+ (+0.00%)

10/06/21 Jefferies
Acceleron initiated with a Hold at Jefferies
10/04/21 Raymond James
Acceleron downgraded to Market Perform from Strong Buy at Raymond James
10/01/21 Barclays
Acceleron downgraded to Equal Weight from Overweight at Barclays
GOSS Gossamer Bio
$10.91 /

+0.07 (+0.65%)

11/09/21 Cantor Fitzgerald
Gossamer Bio assumed with an Overweight at Cantor Fitzgerald
09/20/21 Piper Sandler
Gossamer Bio assumed with an Overweight at Piper Sandler
03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
UTHR United Therapeutics
$189.57 /

+0.41 (+0.22%)

11/08/21 Needham
Liquidia Technologies price target raised to $8 from $5 at Needham
07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
PHAS PhaseBio
$1.92 /

-0.16 (-7.69%)

10/13/21 Stifel
PhaseBio resumed with a Buy at Stifel
05/14/21 William Blair
PhaseBio remains 'significantly undervalued,' says William Blair
03/16/21 Needham
PhaseBio price target raised to Street high $19 at Needham
TENX Tenax Therapeutics
$1.23 /

-0.05 (-3.91%)

11/26/21 H.C. Wainwright
Tenax operational achievements underappreciated, says H.C. Wainwright
12/29/20 H.C. Wainwright
Tenax Therapeutics initiated with a Buy at H.C. Wainwright
AVTE Aerovate Therapeutics
$13.43 /

-0.3 (-2.18%)

07/26/21 Cowen
Aerovate Therapeutics initiated with an Outperform at Cowen
07/26/21 Evercore ISI
Aerovate Therapeutics initiated with an Outperform at Evercore ISI
07/26/21 Jefferies
Jefferies starts Aerovate at Buy, sees potential for significant upside
07/26/21 Wedbush
Wedbush bullish on Aerovate Therapeutics, initiates with an Outperform
XLRN Acceleron
$178.79 /

+ (+0.00%)

UTHR United Therapeutics
$189.57 /

+0.41 (+0.22%)

PHAS PhaseBio
$1.92 /

-0.16 (-7.69%)

PFE Pfizer
$55.02 /

+1.3 (+2.42%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

INSM Insmed
$27.07 /

-0.44 (-1.60%)

GOSS Gossamer Bio
$10.91 /

+0.07 (+0.65%)

AVTE Aerovate Therapeutics
$13.43 /

-0.3 (-2.18%)

  • 30
    Jun
  • 11
    May
  • 18
    Mar
XLRN Acceleron
$178.79 /

+ (+0.00%)

PFE Pfizer
$55.02 /

+1.3 (+2.42%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

XLRN Acceleron
$178.79 /

+ (+0.00%)

UTHR United Therapeutics
$189.57 /

+0.41 (+0.22%)

PHAS PhaseBio
$1.92 /

-0.16 (-7.69%)

PFE Pfizer
$55.02 /

+1.3 (+2.42%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

AVTE Aerovate Therapeutics
$13.43 /

-0.3 (-2.18%)

PFE Pfizer
$55.02 /

+1.3 (+2.42%)

JNJ Johnson & Johnson
$158.65 /

+2.69 (+1.72%)

Over a week ago
Recommendations
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel » 09:45
11/18/21
11/18
09:45
11/18/21
09:45
INSM

Insmed

$30.37 /

+0.02 (+0.07%)

, DRNA

Dicerna

$37.97 /

+16.68 (+78.35%)

, NVO

Novo Nordisk

$115.26 /

+0.74 (+0.65%)

, XLRN

Acceleron

$179.55 /

-0.04 (-0.02%)

, MRK

Merck

$82.38 /

-0.22 (-0.27%)

After Dicerna (DRNA)…

After Dicerna (DRNA) partner Novo Nordisk (NVO) agreed to acquire Dicerna for $38.25 per share, representing a roughly 80% premium to yesterday's closing price, Stifel analyst Stephen Willey said he was "a bit surprised" to see Novo emerge as the buyer, but added that he doesn't anticipate another suitor to emerge. He finds it "interesting to note" that most investors recognized the inherent scarcity value of Dicerna's RNAi technology and were aware of the significant discount at which the stock traded, but that many of these investors also struggled with a perceived lack of catalysts over the coming months and years. He views Insmed (INSM) as fitting the same profile of being perceived by most to be fundamentally attractive from a valuation perspective, but also deemed to be "mostly irrelevant from a meaningful catalyst perspective over the next 6-12+ months," Willey said. The analyst, who adds that Merck's (MRK) recently-proposed acquisition of Acceleron (XLRN) "seems to establish some interesting precedence" in terms of targets with multi-billion dollar valuations largely-predicated on a binary event, noted that he is "not in possession of any information which would suggest INSM, or any other company within our coverage universe, is currently a target of any strategic transaction." Willey maintains a Buy rating and $43 price target on Insmed shares.

ShowHide Related Items >><<
XLRN Acceleron
$179.55 /

-0.04 (-0.02%)

NVO Novo Nordisk
$115.26 /

+0.74 (+0.65%)

MRK Merck
$82.38 /

-0.22 (-0.27%)

DRNA Dicerna
$37.97 /

+16.68 (+78.35%)

INSM Insmed
$30.37 /

+0.02 (+0.07%)

10/19/21 Morgan Stanley
Insmed assumed with an Overweight at Morgan Stanley
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
DRNA Dicerna
$37.97 /

+16.68 (+78.35%)

08/11/21 B. Riley
Dicerna price target lowered to $35 from $49 at B. Riley
08/10/21 Goldman Sachs
Dicerna downgraded to Neutral from Buy at Goldman Sachs
08/09/21
Fly Intel: Top five analyst downgrades
08/09/21 Citi
Dicerna downgraded to Neutral on 'disappointing' trial data at Citi
NVO Novo Nordisk
$115.26 /

+0.74 (+0.65%)

11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
XLRN Acceleron
$179.55 /

-0.04 (-0.02%)

10/06/21 Jefferies
Acceleron initiated with a Hold at Jefferies
10/04/21 Raymond James
Acceleron downgraded to Market Perform from Strong Buy at Raymond James
10/01/21 Barclays
Acceleron downgraded to Equal Weight from Overweight at Barclays
09/30/21 Cowen
Acceleron downgraded to Market Perform from Outperform at Cowen
MRK Merck
$82.38 /

-0.22 (-0.27%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
XLRN Acceleron
$179.55 /

-0.04 (-0.02%)

NVO Novo Nordisk
$115.26 /

+0.74 (+0.65%)

MRK Merck
$82.38 /

-0.22 (-0.27%)

INSM Insmed
$30.37 /

+0.02 (+0.07%)

DRNA Dicerna
$37.97 /

+16.68 (+78.35%)

  • 11
    May
XLRN Acceleron
$179.55 /

-0.04 (-0.02%)

MRK Merck
$82.38 /

-0.22 (-0.27%)

XLRN Acceleron
$179.55 /

-0.04 (-0.02%)

NVO Novo Nordisk
$115.26 /

+0.74 (+0.65%)

MRK Merck
$82.38 /

-0.22 (-0.27%)

DRNA Dicerna
$37.97 /

+16.68 (+78.35%)

MRK Merck
$82.38 /

-0.22 (-0.27%)

Over a month ago
Earnings
Insmed reports Q3 GAAP EPS (96c), consensus (86c) » 07:34
10/28/21
10/28
07:34
10/28/21
07:34
INSM

Insmed

$26.40 /

-0.465 (-1.73%)

Reports Q3 revenue…

Reports Q3 revenue $46.8M, consensus $49.23M.

ShowHide Related Items >><<
INSM Insmed
$26.40 /

-0.465 (-1.73%)

10/19/21 Morgan Stanley
Insmed assumed with an Overweight at Morgan Stanley
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
INSM Insmed
$26.40 /

-0.465 (-1.73%)

  • 11
    May
INSM Insmed
$26.40 /

-0.465 (-1.73%)

Initiation
Insmed assumed with an Overweight at Morgan Stanley » 08:23
10/19/21
10/19
08:23
10/19/21
08:23
INSM

Insmed

$26.37 /

-0.13 (-0.49%)

Morgan Stanley analyst…

Morgan Stanley analyst Jeffrey Hung assumed coverage of Insmed with an Overweight rating with a price target of $52, down from $56. Shares will be driven by U.S. sales of Arikayce in the near-term, contends Hung, who said that though Arikayce faced some headwinds during COVID, there have been "early indications of returning to normal." He also believes Europe and Japan will be sources of meaningful growth "over time," added Hung.

ShowHide Related Items >><<
INSM Insmed
$26.37 /

-0.13 (-0.49%)

10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
INSM Insmed
$26.37 /

-0.13 (-0.49%)

  • 11
    May
INSM Insmed
$26.37 /

-0.13 (-0.49%)

Initiation
Insmed initiated with an Overweight at Cantor Fitzgerald » 07:12
10/08/21
10/08
07:12
10/08/21
07:12
INSM

Insmed

$27.62 /

+0.17 (+0.62%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Jennifer Kim initiated coverage of Insmed with an Overweight rating and $60 price target. Kim believe Insmed is approaching an inflection point as it executes on becoming a self-sustaining, leading rare disease company, the analyst tells investors in a research note. Kim adds that Insmed is well-capitalized to deliver on its pipeline, and feels that upwards earnings estimate revisions, driven by product and pipeline advancements, should move the stock higher.

ShowHide Related Items >><<
INSM Insmed
$27.62 /

+0.17 (+0.62%)

10/08/21 Cantor Fitzgerald
Insmed initiated with an Overweight at Cantor Fitzgerald
04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
INSM Insmed
$27.62 /

+0.17 (+0.62%)

  • 11
    May
INSM Insmed
$27.62 /

+0.17 (+0.62%)

Initiation
Insmed initiated with an Overweight at Cantor Fitzgerald » 06:22
10/08/21
10/08
06:22
10/08/21
06:22
INSM

Insmed

$27.62 /

+0.17 (+0.62%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Jennifer Kim initiated coverage of Insmed with an Overweight rating and $60 price target.

ShowHide Related Items >><<
INSM Insmed
$27.62 /

+0.17 (+0.62%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
INSM Insmed
$27.62 /

+0.17 (+0.62%)

  • 11
    May
INSM Insmed
$27.62 /

+0.17 (+0.62%)

Conference/Events
SVB Leerink to hold a virtual event » 04:55
09/23/21
09/23
04:55
09/23/21
04:55
AVRO

Avrobio

$6.12 /

-0.1 (-1.61%)

, CRNX

Crinetics

$20.88 /

-0.01 (-0.05%)

, INSM

Insmed

$26.66 /

+0.03 (+0.11%)

, MREO

Mereo BioPharma

$2.53 /

+ (+0.00%)

, ORTX

Orchard Therapeutics

$2.41 /

-0.065 (-2.63%)

, RPHM

Reneo Pharmaceuticals

$8.09 /

+0.36 (+4.66%)

, SPRB

Spruce Biosciences

$6.40 /

-0.11 (-1.69%)

, TALS

Talaris Therapeutics

$14.68 /

+0.37 (+2.59%)

Neuromuscular, Rare…

Neuromuscular, Rare Diseases & Genetic Medicines Virtual Event to be held on September 22-23.

ShowHide Related Items >><<
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
06/18/21 JPMorgan
Crinetics upgraded to Overweight from Neutral at JPMorgan
05/03/21 JonesTrading
Crinetics initiated with a Buy at JonesTrading
11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
INSM Insmed
$26.66 /

+0.03 (+0.11%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

05/05/21
Fly Intel: Top five analyst initiations
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/05/21 Needham
Mereo BioPharma initiated with a Buy at Needham
ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

08/18/21 JPMorgan
Orchard Therapeutics downgraded to Neutral from Overweight at JPMorgan
07/02/21 Wedbush
Pharming collaboration offers upside for Orchard Therapeutics, says Wedbush
06/30/21 JPMorgan
Orchard Therapeutics price target lowered to $14 from $15 at JPMorgan
06/30/21 Cantor Fitzgerald
Orchard Therapeutics price target lowered to $12 from $17 at Cantor Fitzgerald
RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

05/20/21 Piper Sandler
Reneo valuation presents 'ideal opportunity,' says Piper Sandler
05/04/21 SVB Leerink
SVB Leerink bullish on Reneo Pharmaceuticals, initiates with an Outperform
05/04/21 SVB Leerink
Reneo Pharmaceuticals initiated with an Outperform at SVB Leerink
05/04/21 Jefferies
Reneo Pharmaceuticals initiated with a Buy at Jefferies
SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

07/19/21 H.C. Wainwright
Spruce Biosciences initiated with a Buy at H.C. Wainwright
04/26/21 Credit Suisse
Spruce Biosciences assumed with an Outperform at Credit Suisse
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 SVB Leerink
SVB Leerink bullish on Spruce Biosciences, initiates with an Outperform
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

06/01/21 SVB Leerink
Talaris Therapeutics initiated with an Outperform at SVB Leerink
06/01/21 Evercore ISI
Evercore starts Talaris Therapeutics at Outperform with $35 price target
06/01/21 Evercore ISI
Talaris Therapeutics initiated with an Outperform at Evercore ISI
06/01/21 Guggenheim
Talaris Therapeutics initiated with a Buy at Guggenheim
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

  • 11
    May
  • 07
    May
  • 08
    Apr
  • 09
    Apr
  • 10
    Feb
  • 20
    Nov
  • 09
    Oct
ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

Conference/Events
SVB Leerink to hold a virtual event » 09:43
09/22/21
09/22
09:43
09/22/21
09:43
AVRO

Avrobio

$6.21 /

-0.01 (-0.16%)

, CRNX

Crinetics

$20.89 /

+ (+0.00%)

, INSM

Insmed

$26.63 /

+ (+0.00%)

, MREO

Mereo BioPharma

$2.53 /

+ (+0.00%)

, ORTX

Orchard Therapeutics

$2.48 /

+ (+0.00%)

, RPHM

Reneo Pharmaceuticals

$7.75 /

+0.02 (+0.26%)

, SPRB

Spruce Biosciences

$6.55 /

+0.04 (+0.61%)

, TALS

Talaris Therapeutics

$14.35 /

+0.04 (+0.28%)

Neuromuscular, Rare…

Neuromuscular, Rare Diseases & Genetic Medicines Virtual Event to be held on September 22-23.

ShowHide Related Items >><<
TALS Talaris Therapeutics
$14.35 /

+0.04 (+0.28%)

SPRB Spruce Biosciences
$6.55 /

+0.04 (+0.61%)

RPHM Reneo Pharmaceuticals
$7.75 /

+0.02 (+0.26%)

ORTX Orchard Therapeutics
$2.48 /

+ (+0.00%)

MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

INSM Insmed
$26.63 /

+ (+0.00%)

CRNX Crinetics
$20.89 /

+ (+0.00%)

AVRO Avrobio
$6.21 /

-0.01 (-0.16%)

AVRO Avrobio
$6.21 /

-0.01 (-0.16%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
CRNX Crinetics
$20.89 /

+ (+0.00%)

06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
06/18/21 JPMorgan
Crinetics upgraded to Overweight from Neutral at JPMorgan
05/03/21 JonesTrading
Crinetics initiated with a Buy at JonesTrading
11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
INSM Insmed
$26.63 /

+ (+0.00%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

05/05/21
Fly Intel: Top five analyst initiations
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/05/21 Needham
Mereo BioPharma initiated with a Buy at Needham
ORTX Orchard Therapeutics
$2.48 /

+ (+0.00%)

08/18/21 JPMorgan
Orchard Therapeutics downgraded to Neutral from Overweight at JPMorgan
07/02/21 Wedbush
Pharming collaboration offers upside for Orchard Therapeutics, says Wedbush
06/30/21 JPMorgan
Orchard Therapeutics price target lowered to $14 from $15 at JPMorgan
06/30/21 Cantor Fitzgerald
Orchard Therapeutics price target lowered to $12 from $17 at Cantor Fitzgerald
RPHM Reneo Pharmaceuticals
$7.75 /

+0.02 (+0.26%)

05/20/21 Piper Sandler
Reneo valuation presents 'ideal opportunity,' says Piper Sandler
05/04/21 SVB Leerink
SVB Leerink bullish on Reneo Pharmaceuticals, initiates with an Outperform
05/04/21 SVB Leerink
Reneo Pharmaceuticals initiated with an Outperform at SVB Leerink
05/04/21 Jefferies
Reneo Pharmaceuticals initiated with a Buy at Jefferies
SPRB Spruce Biosciences
$6.55 /

+0.04 (+0.61%)

07/19/21 H.C. Wainwright
Spruce Biosciences initiated with a Buy at H.C. Wainwright
04/26/21 Credit Suisse
Spruce Biosciences assumed with an Outperform at Credit Suisse
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 SVB Leerink
SVB Leerink bullish on Spruce Biosciences, initiates with an Outperform
TALS Talaris Therapeutics
$14.35 /

+0.04 (+0.28%)

06/01/21 SVB Leerink
Talaris Therapeutics initiated with an Outperform at SVB Leerink
06/01/21 Evercore ISI
Evercore starts Talaris Therapeutics at Outperform with $35 price target
06/01/21 Evercore ISI
Talaris Therapeutics initiated with an Outperform at Evercore ISI
06/01/21 Guggenheim
Talaris Therapeutics initiated with a Buy at Guggenheim
TALS Talaris Therapeutics
$14.35 /

+0.04 (+0.28%)

SPRB Spruce Biosciences
$6.55 /

+0.04 (+0.61%)

ORTX Orchard Therapeutics
$2.48 /

+ (+0.00%)

INSM Insmed
$26.63 /

+ (+0.00%)

CRNX Crinetics
$20.89 /

+ (+0.00%)

AVRO Avrobio
$6.21 /

-0.01 (-0.16%)

  • 11
    May
  • 07
    May
  • 08
    Apr
  • 09
    Apr
  • 10
    Feb
  • 20
    Nov
  • 09
    Oct
ORTX Orchard Therapeutics
$2.48 /

+ (+0.00%)

TALS Talaris Therapeutics
$14.35 /

+0.04 (+0.28%)

RPHM Reneo Pharmaceuticals
$7.75 /

+0.02 (+0.26%)

INSM Insmed
$26.63 /

+ (+0.00%)

CRNX Crinetics
$20.89 /

+ (+0.00%)

CRNX Crinetics
$20.89 /

+ (+0.00%)

Over a quarter ago
Earnings
Insmed reports Q2 GAAP EPS ($1.07), consensus (85c) » 07:56
08/05/21
08/05
07:56
08/05/21
07:56
INSM

Insmed

$24.77 /

+0.75 (+3.12%)

Reports Q2 revenue…

Reports Q2 revenue $45.4M, consensus $43.72M. "Insmed made meaningful progress in the second quarter of 2021, with important achievements across our four pillars-ARIKAYCE, brensocatib, TPIP, and translational medicine," commented Will Lewis, Chair and CEO of Insmed. "With the launch of ARIKAYCE just last month in Japan, the largest market for refractory MAC lung disease that we are pursuing, we're thrilled that our lead product is now available in three major territories. We continue to enroll patients in both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease in line with expectations, and we are advancing TPIP to Phase 2 development in both PAH and PH-ILD. As we carry forward learnings from the past year and a half in navigating the pandemic, we have great confidence in our ability to execute on our commercial and clinical activities around the world."

ShowHide Related Items >><<
INSM Insmed
$24.77 /

+0.75 (+3.12%)

INSM Insmed
$24.77 /

+0.75 (+3.12%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
INSM Insmed
$24.77 /

+0.75 (+3.12%)

  • 11
    May
INSM Insmed
$24.77 /

+0.75 (+3.12%)

Conference/Events
Berenberg to hold a virtual conference » 04:55
05/19/21
05/19
04:55
05/19/21
04:55
ABCL

AbCellera

$32.93 /

-1.19 (-3.49%)

, EXPO

Exponent

$92.22 /

-1.19 (-1.27%)

, TNDM

TNDM

/

+

, TREX

Trex Company

$99.30 /

-2.54 (-2.49%)

, BUD

AB InBev

$74.79 /

-0.63 (-0.84%)

, AKZOY

AkzoNobel

$41.91 /

+0.17 (+0.41%)

, ALGN

Align Technology

$570.00 /

+10.83 (+1.94%)

, ALSMY

Alstom

$5.44 /

+0.11 (+2.06%)

, ASND

Ascendis Pharma

$138.11 /

+2.75 (+2.03%)

, BAESY

BAE Systems

$29.73 /

-0.13 (-0.44%)

, BCS

Barclays

$10.29 /

-0.06 (-0.58%)

, BAYRY

Bayer

$17.13 /

-0.08 (-0.46%)

, CMPGY

Compass Group

$22.04 /

+0.208 (+0.95%)

, GSK

GlaxoSmithKline

$39.56 /

-0.025 (-0.06%)

, IFX

use symbol IFNNY

$2.49 /

+ (+0.00%)

, INSP

Inspire Medical

$175.29 /

+7.02 (+4.17%)

, INSM

Insmed

$26.08 /

+0.07 (+0.27%)

, GNL

Global Net Lease

$18.82 /

+0.11 (+0.59%)

, EVTCY

Evotec

$80.50 /

+ (+0.00%)

, ZBRA

Zebra Technologies

$477.97 /

-4.99 (-1.03%)

, SMMNY

Siemens Healthineers

$28.39 /

-0.19 (-0.66%)

, OMCL

Omnicell

$133.95 /

+1.815 (+1.37%)

, MRK

Merck

$79.38 /

-0.49 (-0.61%)

, NVO

Novo Nordisk

$79.65 /

-0.9 (-1.12%)

Berenberg Virtual…

Berenberg Virtual Conference USA 2021 will be held on May 18-19.

ShowHide Related Items >><<
ZBRA Zebra Technologies
$477.97 /

-4.99 (-1.03%)

TREX Trex Company
$99.30 /

-2.54 (-2.49%)

TNDM TNDM
/

+

OMCL Omnicell
$133.95 /

+1.815 (+1.37%)

NVO Novo Nordisk
$79.65 /

-0.9 (-1.12%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

INSP Inspire Medical
$175.29 /

+7.02 (+4.17%)

INSM Insmed
$26.08 /

+0.07 (+0.27%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GNL Global Net Lease
$18.82 /

+0.11 (+0.59%)

EXPO Exponent
$92.22 /

-1.19 (-1.27%)

EVTCY Evotec
$80.50 /

+ (+0.00%)

CMPGY Compass Group
$22.04 /

+0.208 (+0.95%)

BUD AB InBev
$74.79 /

-0.63 (-0.84%)

BCS Barclays
$10.29 /

-0.06 (-0.58%)

BAYRY Bayer
$17.13 /

-0.08 (-0.46%)

BAESY BAE Systems
$29.73 /

-0.13 (-0.44%)

ASND Ascendis Pharma
$138.11 /

+2.75 (+2.03%)

ALSMY Alstom
$5.44 /

+0.11 (+2.06%)

ALGN Align Technology
$570.00 /

+10.83 (+1.94%)

AKZOY AkzoNobel
$41.91 /

+0.17 (+0.41%)

ABCL AbCellera
$32.93 /

-1.19 (-3.49%)

ABCL AbCellera
$32.93 /

-1.19 (-3.49%)

03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
01/26/21 Berenberg
Eli Lilly data 'incrementally positive' for AbCellera, says Berenberg
EXPO Exponent
$92.22 /

-1.19 (-1.27%)

01/20/21 Truist
Exponent price target raised to $105 from $81 at Truist
TNDM TNDM
/

+

05/06/21 SVB Leerink
Tandem Diabetes price target raised to $102 from $95 at SVB Leerink
05/06/21 Oppenheimer
Tandem Diabetes price target raised to $135 from $130 at Oppenheimer
05/06/21 Piper Sandler
Tandem Diabetes remains a 'name to buy' after Q1 beat, says Piper Sandler
03/12/21 Piper Sandler
Tandem Diabetes competition concerns overblown, says Piper Sandler
TREX Trex Company
$99.30 /

-2.54 (-2.49%)

05/12/21 B. Riley
Trex Company price target raised to $103 from $81 at B. Riley
05/11/21 Truist
Trex Company price target raised to $125 from $120 at Truist
05/11/21 BMO Capital
Trex Company price target raised to $98 from $92 at BMO Capital
05/11/21 Baird
Trex Company price target raised to $120 from $110 at Baird
BUD AB InBev
$74.79 /

-0.63 (-0.84%)

05/18/21 Morgan Stanley
AB InBev price target raised to EUR 60 from EUR 56 at Morgan Stanley
05/11/21 RBC Capital
AB InBev price target raised to EUR 76 from EUR 67 at RBC Capital
05/10/21 Berenberg
AB InBev price target raised to EUR 78 from EUR 72.10 at Berenberg
05/07/21 Deutsche Bank
AB InBev price target raised to EUR 59 from EUR 55 at Deutsche Bank
AKZOY AkzoNobel
$41.91 /

+0.17 (+0.41%)

05/18/21 Barclays
AkzoNobel price target raised to EUR 119 from EUR 114 at Barclays
04/14/21 UBS
AkzoNobel price target raised to EUR 97 from EUR 89 at UBS
02/23/21 UBS
AkzoNobel price target lowered to EUR 89 from EUR 91 at UBS
01/19/21 Deutsche Bank
AkzoNobel downgraded to Hold from Buy at Deutsche Bank
ALGN Align Technology
$570.00 /

+10.83 (+1.94%)

04/29/21 SVB Leerink
Align Technology price target raised to $770 from $690 at SVB Leerink
04/29/21 Credit Suisse
Align Technology price target raised to $715 from $693 at Credit Suisse
04/29/21 Stifel
Align Technology price target raised to $750 from $650 at Stifel
04/29/21 Baird
Align Technology price target raised to $745 from $655 at Baird
ALSMY Alstom
$5.44 /

+0.11 (+2.06%)

05/17/21 UBS
Alstom price target raised to EUR 55 from EUR 50 at UBS
05/17/21 Societe Generale
Alstom price target lowered to EUR 53 from EUR 55 at Societe Generale
05/14/21 Credit Suisse
Alstom price target lowered to EUR 51 from EUR 52 at Credit Suisse
05/13/21 JPMorgan
Alstom price target lowered to EUR 49 from EUR 51 at JPMorgan
ASND Ascendis Pharma
$138.11 /

+2.75 (+2.03%)

05/11/21 JPMorgan
Ascendis shares offer 'very compelling entry point,' says JPMorgan
04/13/21 Canaccord
Ascendis Pharma oncology platform remains underappreciated, says Canaccord
03/30/21 Oppenheimer
Ascendis Pharma downgraded to Perform from Outperform at Oppenheimer
03/25/21 JPMorgan
Ascendis 25% selloff brings 'compelling' entry point, says JPMorgan
BAESY BAE Systems
$29.73 /

-0.13 (-0.44%)

04/14/21 Morgan Stanley
BAE Systems price target lowered to 640 GBp from 647 GBp at Morgan Stanley
04/09/21 Exane BNP Paribas
BAE Systems downgraded to Neutral from Outperform at Exane BNP Paribas
03/30/21 Bernstein
BAE Systems upgraded to Outperform from Market Perform at Bernstein
03/24/21 Deutsche Bank
BAE Systems price target raised to 670 GBp from 660 GBp at Deutsche Bank
BCS Barclays
$10.29 /

-0.06 (-0.58%)

05/05/21 Berenberg
Barclays price target raised to 220 GBp from 180 GBp at Berenberg
05/04/21 Societe Generale
Barclays price target raised to 170 GBp from 150 GBp at Societe Generale
05/04/21 Investec
Barclays upgraded to Buy from Hold at Investec
04/23/21 UBS
Barclays price target raised to 195 GBp from 180 GBp at UBS
BAYRY Bayer
$17.13 /

-0.08 (-0.46%)

05/18/21 JPMorgan
Bayer upgraded to Overweight from Neutral at JPMorgan
05/14/21 Berenberg
Bayer price target raised to EUR 74 from EUR 68 at Berenberg
05/13/21 Credit Suisse
Bayer price target raised to EUR 60 from EUR 56 at Credit Suisse
05/13/21 Bryan Garnier
Bayer upgraded to Neutral from Sell at Bryan Garnier
CMPGY Compass Group
$22.04 /

+0.208 (+0.95%)

05/17/21 RBC Capital
Compass Group price target raised to 1,225 GBp from 1,000 GBp at RBC Capital
05/17/21 Exane BNP Paribas
Compass Group upgraded to Outperform from Neutral at Exane BNP Paribas
05/14/21 Barclays
Compass Group price target raised to 1,720 GBp from 1,640 GBp at Barclays
05/13/21 Barclays
Compass Group price target raised to 1,720 GBp from 1,640 GBp at Barclays
GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
IFX use symbol IFNNY
$2.49 /

+ (+0.00%)

INSP Inspire Medical
$175.29 /

+7.02 (+4.17%)

05/12/21 JPMorgan
JPMorgan sees four 'compelling' MedTech opportunities after selloff
05/06/21 Piper Sandler
Inspire Medical pullback brings attractive entry point, says Piper Sandler
05/05/21 Lake Street
Inspire Medical price target raised to $260 from $250 at Lake Street
05/05/21 Piper Sandler
Inspire Medical price target raised to $255 from $252 at Piper Sandler
INSM Insmed
$26.08 /

+0.07 (+0.27%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
GNL Global Net Lease
$18.82 /

+0.11 (+0.59%)

03/01/21 B. Riley
Global Net Lease price target raised to $23 from $21 at B. Riley Securities
09/22/20 Ladenburg
Ladenburg stays Neutral on Global Net Lease due to growth headwinds
06/30/20 Berenberg
Global Net Lease initiated with a Buy at Berenberg
06/08/20 JMP Securities
Global Net Lease resumed with a Market Perform at JMP Securities
EVTCY Evotec
$80.50 /

+ (+0.00%)

05/11/21 RBC Capital
Evotec upgraded to Outperform from Sector Perform at RBC Capital
04/22/21 Deutsche Bank
Evotec price target raised to EUR 33 from EUR 29 at Deutsche Bank
03/05/21 Citi
Evotec downgraded to Neutral from Buy at Citi
01/28/21 RBC Capital
Evotec downgraded to Sector Perform from Outperform at RBC Capital
ZBRA Zebra Technologies
$477.97 /

-4.99 (-1.03%)

04/21/21
Fly Intel: Top five analyst downgrades
04/21/21 Morgan Stanley
Zebra downgraded to Underweight from Equal Weight at Morgan Stanley
03/23/21 Northcoast
Zebra Technologies upgraded to Buy from Neutral at Northcoast
02/12/21 Needham
Zebra Technologies price target raised to $515 from $445 at Needham
SMMNY Siemens Healthineers
$28.39 /

-0.19 (-0.66%)

05/04/21 JPMorgan
Siemens Healthineers price target lowered to EUR 54.40 at JPMorgan
05/04/21 Credit Suisse
Siemens Healthineers price target raised to EUR 55 from EUR 54 at Credit Suisse
05/04/21 Deutsche Bank
Siemens Healthineers upgraded to Buy from Hold at Deutsche Bank
04/30/21 Barclays
Siemens Healthineers price target raised to EUR 47 from EUR 41 at Barclays
OMCL Omnicell
$133.95 /

+1.815 (+1.37%)

04/30/21 Benchmark
Omnicell price target raised to $160 from $155 at Benchmark
04/30/21 Piper Sandler
Omnicell price target raised to $152 from $147 at Piper Sandler
03/22/21 Benchmark
Omnicell price target raised to $155 from $140 at Benchmark
02/02/21
Fly Intel: Top five analyst upgrades
MRK Merck
$79.38 /

-0.49 (-0.61%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
NVO Novo Nordisk
$79.65 /

-0.9 (-1.12%)

02/11/21 UBS
Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS
02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
ZBRA Zebra Technologies
$477.97 /

-4.99 (-1.03%)

TREX Trex Company
$99.30 /

-2.54 (-2.49%)

TNDM TNDM
/

+

SMMNY Siemens Healthineers
$28.39 /

-0.19 (-0.66%)

OMCL Omnicell
$133.95 /

+1.815 (+1.37%)

NVO Novo Nordisk
$79.65 /

-0.9 (-1.12%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

INSP Inspire Medical
$175.29 /

+7.02 (+4.17%)

INSM Insmed
$26.08 /

+0.07 (+0.27%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

EXPO Exponent
$92.22 /

-1.19 (-1.27%)

BUD AB InBev
$74.79 /

-0.63 (-0.84%)

BCS Barclays
$10.29 /

-0.06 (-0.58%)

BAYRY Bayer
$17.13 /

-0.08 (-0.46%)

ASND Ascendis Pharma
$138.11 /

+2.75 (+2.03%)

ALGN Align Technology
$570.00 /

+10.83 (+1.94%)

ABCL AbCellera
$32.93 /

-1.19 (-3.49%)

  • 11
    May
  • 11
    Dec
  • 08
    Jul
TREX Trex Company
$99.30 /

-2.54 (-2.49%)

SMMNY Siemens Healthineers
$28.39 /

-0.19 (-0.66%)

OMCL Omnicell
$133.95 /

+1.815 (+1.37%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

BUD AB InBev
$74.79 /

-0.63 (-0.84%)

BCS Barclays
$10.29 /

-0.06 (-0.58%)

BAYRY Bayer
$17.13 /

-0.08 (-0.46%)

BAESY BAE Systems
$29.73 /

-0.13 (-0.44%)

ALSMY Alstom
$5.44 /

+0.11 (+2.06%)

TREX Trex Company
$99.30 /

-2.54 (-2.49%)

OMCL Omnicell
$133.95 /

+1.815 (+1.37%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

INSP Inspire Medical
$175.29 /

+7.02 (+4.17%)

INSM Insmed
$26.08 /

+0.07 (+0.27%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

EXPO Exponent
$92.22 /

-1.19 (-1.27%)

BUD AB InBev
$74.79 /

-0.63 (-0.84%)

BCS Barclays
$10.29 /

-0.06 (-0.58%)

BAYRY Bayer
$17.13 /

-0.08 (-0.46%)

BAESY BAE Systems
$29.73 /

-0.13 (-0.44%)

ALGN Align Technology
$570.00 /

+10.83 (+1.94%)

ABCL AbCellera
$32.93 /

-1.19 (-3.49%)

ZBRA Zebra Technologies
$477.97 /

-4.99 (-1.03%)

NVO Novo Nordisk
$79.65 /

-0.9 (-1.12%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

BUD AB InBev
$74.79 /

-0.63 (-0.84%)

BCS Barclays
$10.29 /

-0.06 (-0.58%)

ALGN Align Technology
$570.00 /

+10.83 (+1.94%)

ABCL AbCellera
$32.93 /

-1.19 (-3.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.